A Phase I, Open-label, Crossover Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults

Trial Identifier: D7961C00005
Sponsor: AstraZeneca
Collaborator:
Parexel
Start Date: March 2026
Primary Completion Date: May 2026
Study Completion Date: May 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

No locations posted.